Related Experiment Video
Updated: Jul 3, 2026
07:20
Assaying for Inorganic Polyphosphate in Bacteria
Published on: January 21, 2019
Polyphosphate as a general procoagulant agent
1Department of Internal Medicine, College of Medicine, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA. sasmith6@uiuc.edu
Journal of Thrombosis and Haemostasis : JTH
|July 31, 2008
Summary
Polyphosphate, released by platelets, accelerates blood clotting. This study shows polyphosphate can reverse anticoagulant effects and aid bleeding treatment in hemophilia patients.
Area of Science:
- Biochemistry
- Hematology
- Hemostasis
Background:
- Polyphosphate is secreted by activated platelets.
- Polyphosphate accelerates blood clotting by triggering the contact pathway and promoting Factor V activation.
Purpose of the Study:
- To investigate the procoagulant effects of polyphosphate in hemophilia and in the presence of anticoagulants.
- To determine if polyphosphate can reverse the effects of anticoagulant drugs.
Main Methods:
- Assessed polyphosphate's effect on clotting time in hemophilia A and B plasmas.
- Evaluated polyphosphate's impact on clotting dynamics in whole blood with various anticoagulants using thromboelastography.
- Investigated polyphosphate's mechanism of action by studying its effect on Factor V activation.
Main Results:
- Polyphosphate significantly shortened clotting times in hemophilia A and B plasmas.
- Polyphosphate reversed the anticoagulant effects of heparin, enoxaparin, argatroban, and rivaroxaban, normalizing clotting dynamics.
- Polyphosphate antagonizes anticoagulant effects by accelerating Factor V activation.
Conclusions:
- Polyphosphate demonstrates potential for reversing anticoagulation.
- Polyphosphate may be beneficial in treating bleeding episodes in hemophilia patients.
More Related Videos
04:37Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
Published on: May 23, 2025
05:49Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
Published on: November 29, 2024
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:06Coagulation
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
01:09Coagulation
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:22EDTA: Chemistry and Properties
Polydentate ligands are most widely used in complexometric titrations because they form more stable complexes with the metal ions than mono- or bidentate ligands due to the chelate effect. Examples of polydentate ligands are ethylenediaminetetraacetic acid (EDTA), crown ethers, and cryptands. The most important feature of optimal polydentate ligands is the ability to form 1:1 complexes in a single-step process. Amino carboxylic acid derivatives are frequently used as complexing agents. EDTA is...